Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa

Evolutionary Applications

Volumn 9, Issue 4, 2016, Pages 583-595

  Torres Barceló, Clara ^a   Franzon, Blaise ^a   Vasse, Marie ^a   Hochberg, Michael E ^a,b  

^a INSTITUT DES SCIENCES DE L EVOLUTION   (France)

^b SANTA FE INSTITUTE   (United States)

Author keywords

Antibiotics; Bacteriophage; Combination therapies; Evolution; Pseudomonas aeruginosa; Resistance; Virulence

Indexed keywords

EID: 84959421698     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/eva.12364     Document Type: Article

References (64)

1. Andersson, D. I., and D. Hughes 2014. Microbiological effects of sublethal levels of antibiotics. Nature Reviews Microbiology 12:465-478.
2. Bates, D. M., and J. M. Chambers 1992. Nonlinear models. In: J. M. Chambers, and T. J. Hastie, eds. Statistical Models in S, pp. 421-454. Wadsworth, Pacific Grove, CA.
3. Beceiro, A., M. Tomás, and G. Bou 2013. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clinical Microbiology Reviews 26:185-230.
4. Betts, A., M. Vasse, O. Kaltz, and M. E. Hochberg 2013. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evolutionary Applications 6:1054-1063.
5. Betts, A., O. Kaltz, and M. E. Hochberg 2014. Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages. Proceedings of the National Academy of Sciences of the United States of America 111:11109-11114.
6. Bikard, D., and L. A. Marraffini 2012. Innate and adaptive immunity in bacteria: mechanisms of programmed genetic variation to fight bacteriophages. Current Opinion in Immunology 24:15-20.
7. Bland, J. M., and D. G. Altman 1998. Survival probabilities (the Kaplan-Meier method). The British Medical Journal 317:1572.
8. Breidenstein, E. B., C. de la Fuente-Núñez, and R. E. Hancock 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends in Microbiology 19:419-426.
9. Bruttin, A., and H. Brussow 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrobials Agents and Chemotherapy 49:2874-2878.
10. Ceyssens, P.-J., R. Lavigne, W. Mattheus, A. Chibeu, K. Hertveldt, J. Mast et al. 2006. Genomic analysis of Pseudomonas aeruginosa phages LKD16 and LKA1: establishment of the φKMV subgroup within the T7 supergroup. Journal of Bacteriology 188:6924-6931.
11. Chhibber, S., T. Kaur, and K. Sandeep 2013. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE 8:e56022.
12. Cirz, R. T., B. M. O'Neill, J. A. Hammond, S. R. Head, and F. E. Romesberg 2006. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. Journal of Bacteriology 188:7101-7110.
13. Comeau, A. M., F. Tetart, S. N. Trojet, M.-F. Prere, and H. M. Krisch 2007. Phage-Antibiotic Synergy (PAS): b-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2:e799. doi: 10.1371/journal.pone.0000799.
14. Coulter, L. B., R. J. McLean, R. E. Rohde, and G. M. Aron 2014. Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6:3778-3786.
15. Ekstrom, C. T. 2011. Manipulating data. In: H. Chapman, ed. The R Primer, pp. 64-66. CRC Press, London, UK.
16. Escobar-Páramo, P., C. Gougat-Barbera, and M. E. Hochberg 2012. Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evolutionary Applications 5:583-592.
17. Evans, T. J., A. Trauner, E. Komitopoulou, and G. P. Salmond 2010. Exploitation of a new flagellatropic phage of Erwinia for positive selection of bacterial mutants attenuated in plant virulence: towards phage therapy. Journal of Applied Microbiology 108:676-685.
18. Filippov, A. A., K. V. Sergueev, Y. He, X.-Z. Huang, B. T. Gnade, A. J. Mueller, C. M. Fernandez-Prada et al. 2011. Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. PLoS ONE 6:e25486.
19. Fortier, L. C., and O. Sekulovic 2013. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4:354-365.
20. Fruciano, D. E., and S. Bourne 2007. Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West. Canadian Journal of Infectious Diseases & Medical Microbiology 18:19-26.
21. Fu, W., T. Forster, O. Mayer, J. J. Curtin, S. M. Lehman, and R. M. Donlan 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrobials Agents and Chemotherapy 54:397.
22. Godlewska, R., K. Wiśniewska, Z. Pietras, and E. K. Jagusztyn-Krynicka 2009. Peptidoglycan-associated lipoprotein (Pal) of Gram-negative bacteria: function, structure, role in pathogenesis and potential application in immunoprophylaxis. FEMS Microbiology Letters 298:1-11.
23. Gonzalez, D., S. Schmidt, and H. Derendorf 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clinical Microbiology Reviews 26:274-288.
24. Haddadin, R. N., S. Saleh, I. S. Al-Adham, T. E. Buultjens, and P. J. Collier 2010. The effect of subminimal inhibitory concentrations of antibiotics on virulence factors expressed by Staphylococcus aureus biofilms. Journal of Applied Microbiology 108:1281-1291.
25. Hagens, S., A. Habel, and U. Bläsi 2006. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microbial Drug Resistance 12:164-168.
26. Hagihara, M., J. L. Crandon, and D. P. Nicolau 2012. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opinion on Drug Safety 11:221-233.
27. Hall, A. R., D. De Vos, V. P. Friman, J. P. Pirnay, and A. Buckling 2012. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Applied and Environmental Microbiology 78:5646-5652.
28. Hendry, A. P., M. T. Kinnison, M. Heino, T. Day, T. B. Smith, G. Fitt, C. T. Bergstrom et al. 2011. Evolutionary principles and their practical application. Evolutionary Applications 4:159-183.
29. Hernandez, V., T. Cr pin, A. Palencia, S. Cusack, T. Akama, S. J. Baker, W. Bu et al. 2013. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrobials Agents and Chemotherapy 57:1394-1403.
30. Holt, R. D., and M. E. Hochberg 1997. When is biological control evolutionarily stable (or is it)? Ecology 78:1673-1683.
31. Hosseinidoust, Z., T. G. M. van de Ven, and N. Tufenkji 2013. Evolution of Pseudomonas aeruginosa virulence as a result of phage predation. Applied and Environmental Microbiology 79:6110-6116.
32. Hughes, D., and D. I. Andersson 2012. Selection of resistance at lethal and non-lethal antibiotic concentrations. Current Opinion in Microbiology 15:555-560.
33. Kahm, M., G. Hasenbrink, H. Lichtenberg-Frate, J. Ludwig, and M. Kschischo 2010. grofit: fitting biological growth curves with R. Journal of Statistical Software 33:1-21.
34. Kim, S., T. D. Lieberman, and R. Kishony 2014. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proceedings of the National Academy of Sciences of the United States of America 111:14494-14499.
35. Kirby, A. E. 2012. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS ONE 7:e51017.
36. Knezevic, P., S. Curcin, V. Aleksic, M. Petrusic, and L. Vlaski 2013. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Research in Microbiology 164:55-60.
37. Kouyos, R. D., C. J. Metcalf, R. Birger, E. Y. Klein, P. Abel zur Wiesch, P. Ankomah, N. Arinaminpathy et al. 2014. The path of least resistance: aggressive or moderate treatment? Proceedings of the Royal Society B: Biological Sciences 281:20140566.
38. Kwan, T., J. Liu, M. DuBow, P. Gros, and J. Pelletier 2005. The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proceedings of the National Academy of Sciences of the United States of America 102:5174-5179.
39. Laanto, E., J. K. Bamford, J. Laakso, and L. R. Sundberg 2012. Phage-driven loss of virulence in a fish pathogenic bacterium. PLoS ONE 7:e53157.
40. Laxminarayan, R., A. Duse, C. Wattal, A. K. M. Zaidi, H. F. L. Wertheim, N. Sumpradit, E. Vlieghe et al. 2013. Antibiotic resistance-the need for global solutions. Lancet Infectious Diseases 13:1057-1098.
41. Leggett, H. C., C. K. Cornwallis, and S. A. West 2012. Mechanisms of pathogenesis, infective dose and virulence in human parasites. PLoS Pathogens 8:e1002512.
42. Loewe, S. 1953. The problem of synergism and antagonism of combined drugs. Arzneimittel-Forschung 3:285-290.
43. Lood, R., B. Y. Winer, A. J. Pelzek, R. Diez-Martinez, M. Thandar, C. W. Euler, R. Schuch et al. 2015. Novel phage lysins capable of killing the multidrug resistant Gram-negative bacterium Acinetobacter baumannii in a mouse sepsis model. Antimicrobials Agents and Chemotherapy 59:1983-1991.
44. Lu, T. K., and J. J. Collins 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proceedings of the National Academy of Sciences of the United States of America 106:4629-4634.
45. Mesaros, N., P. Nordmann, P. Pl siat, M. Roussel-Delvallez, J. Van e Eldere, Y. Glupczynski, Y. Van Laethem et al. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology and Infection 13:560-578.
46. Orr, H. A., and R. L. Unckless 2014. The population genetics of evolutionary rescue. PLoS Genetics 10:e1004551.
47. Paul, M., and L. Leibovici 2013. Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? Clinical Infectious Diseases 57:217-220.
48. Pena-Miller, R., D. Laehnemann, G. Jansen, A. Fuentes-Hernandez, P. Rosenstiel, H. Schulenburg, and R. Beardmore 2013. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biology 11:e1001540. doi: 10.1371/journal.pbio.1001540.
49. Ramsayer, J., O. Kaltz, and M. E. Hochberg 2013. Evolutionary rescue in populations of Pseudomonas fluorescens across an antibiotic gradient. Evolutionary Applications 6:608-616. doi: 10.1111/eva.12046.
50. Read, A. F., T. Day, and S. Huijben 2011. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 108:10871-10877.
51. Ryan, E. M., M. Y. Alkawareek, R. F. Donnelly, and B. F. Gilmore 2012. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunology & Medical Microbiology 65:395-398.
52. Sarker, S. A., S. McCallin, C. Barretto, A. C. Pittet, S. Sultana, L. Krause, S. Huq et al. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434:222-232.
53. Scanlan, P. D., A. R. Hall, G. Blackshields, V. P. Friman, M. R. Davis Jr, J. B. Goldberg, and A. Buckling . 2015. Coevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations. Molecular Biology and Evolution 32:1425-1435.
54. Seed, K. D., M. Yen, B. J. Shapiro, I. J. Hilaire, R. C. Charles, J. E. Teng, L. C. Ivers et al. 2014. Evolutionary consequences of intra-patient phage predation on microbial populations. Elife 26:e03497. doi: 10.7554/eLife.03497.
55. Torres-Barceló, C., F. I. Arias-Sánchez, M. Vasse, J. Ramsayer, O. Kaltz, and M. E. Hochberg 2014. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS ONE 9:e106628.
56. Torres-Barceló, C., and M. E. Hochberg Evolutionary rationale for phages as complements to antibiotics. Trends in Microbiology. doi: 10.1016/j.tim.2015.12.011 [Epub ahead of print].
57. Traugott, K. A., K. Echevarria, P. Maxwell, K. Green, and J. S. Lewis 2011. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:598-608.
58. Verbeken, G., J.-P. Pirnay, R. Lavigne, S. Jennes, D. De Vos, M. Casteels, and I. Huys . 2014. Call for a dedicated European legal framework for bacteriophage therapy. Archivum Immunologiae et Therapiae Experimentalis 62:117-129.
59. Verma, V., K. Harjai, and S. Chhibber 2010. Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. Journal of Antimicrobial Chemotherapy 64:1212-1218.
60. Viertel, T. M., K. Ritter, and H. P. Horz 2014. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. Journal of Antimicrobial Chemotherapy 69:2326-2336.
61. Weitz, J. S., T. Poisot, J. R. Meyer, C. O. Flores, S. Valverde, M. B. Sullivan, and M. E. Hochberg 2013. Phage-bacteria infection networks. Trends in Microbiology 21:82-91.
62. Wright, A., C. H. Hawkins, E. E. Anggårdm, and D. R. Harper 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology 34:349.
63. Zak, O., and F. Kradolfer 1979. Effects of subminimal inhibitory concentrations of antibiotics in experimental infections. Reviews of Infectious Diseases 1:862-879.
64. Zhang, Q. G., and A. Buckling 2012. Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evolutionary Applications 5:575-582.